186 related articles for article (PubMed ID: 35929989)
1. STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.
Qureshy Z; Li H; Zeng Y; Rivera J; Cheng N; Peterson CN; Kim MO; Ryan WR; Ha PK; Bauman JE; Wang SJ; Long SR; Johnson DE; Grandis JR
Clin Cancer Res; 2022 Nov; 28(21):4737-4746. PubMed ID: 35929989
[TBL] [Abstract][Full Text] [Related]
2. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.
Bharadwaj U; Eckols TK; Xu X; Kasembeli MM; Chen Y; Adachi M; Song Y; Mo Q; Lai SY; Tweardy DJ
Oncotarget; 2016 May; 7(18):26307-30. PubMed ID: 27027445
[TBL] [Abstract][Full Text] [Related]
4. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
5. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma.
Adachi M; Cui C; Dodge CT; Bhayani MK; Lai SY
Oral Oncol; 2012 Dec; 48(12):1220-6. PubMed ID: 22770899
[TBL] [Abstract][Full Text] [Related]
6. Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
Mudianto T; Campbell KM; Webb J; Zolkind P; Skidmore ZL; Riley R; Barnell EK; Ozgenc I; Giri T; Dunn GP; Adkins DR; Griffith M; Egloff AM; Griffith OL; Uppaluri R
Clin Cancer Res; 2021 Apr; 27(8):2326-2339. PubMed ID: 33547198
[TBL] [Abstract][Full Text] [Related]
7. Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in
Alam MM; Fermin JM; Knackstedt M; Noonan MJ; Powell T; Goodreau L; Daniel EK; Rong X; Moore-Medlin T; Khandelwal AR; Nathan CO
Oncotarget; 2023 Feb; 14():85-95. PubMed ID: 36745547
[No Abstract] [Full Text] [Related]
8. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
[TBL] [Abstract][Full Text] [Related]
9. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
[TBL] [Abstract][Full Text] [Related]
10. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
[TBL] [Abstract][Full Text] [Related]
11. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
[TBL] [Abstract][Full Text] [Related]
12. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma.
Li F; Shanmugam MK; Chen L; Chatterjee S; Basha J; Kumar AP; Kundu TK; Sethi G
Cancer Prev Res (Phila); 2013 Aug; 6(8):843-54. PubMed ID: 23803415
[TBL] [Abstract][Full Text] [Related]
13. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
[TBL] [Abstract][Full Text] [Related]
14. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
[No Abstract] [Full Text] [Related]
15. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
16. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152.
Wang Y; Wang S; Wu Y; Ren Y; Li Z; Yao X; Zhang C; Ye N; Jing C; Dong J; Zhang K; Sun S; Zhao M; Guo W; Qu X; Qiao Y; Chen H; Kong L; Jin R; Wang X; Zhang L; Zhou J; Shen Q; Zhou X
Mol Cancer Ther; 2017 Apr; 16(4):578-590. PubMed ID: 28138036
[TBL] [Abstract][Full Text] [Related]
18. Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Sun SS; Zhou X; Huang YY; Kong LP; Mei M; Guo WY; Zhao MH; Ren Y; Shen Q; Zhang L
Mol Cancer; 2015 Dec; 14():213. PubMed ID: 26690371
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma.
Zhuang Z; Yu P; Xie N; Wu Y; Liu H; Zhang M; Tao Y; Wang W; Yin H; Zou B; Hou J; Liu X; Li J; Huang H; Wang C
Theranostics; 2020; 10(3):1433-1453. PubMed ID: 31938073
[TBL] [Abstract][Full Text] [Related]
20. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
